PBM Alliance with Walgreens seeks to lower drug costs, improve outcomes

Published Online: Sep 01,2016 Laurie Toich, Assistant Editor Drug costs have become a hot button issue throughout the healthcare and pharmaceutical industries, as patient outcomes and value-based care take center stage. The US Centers for Medicare and Medicaid Services has focused on both aspects of healthcare through proposed rules and payment models, among other cost-controlling actions. Executives at Prime Therapeutics, a …

How will the changes to Medicare Part D impact you?

  In this presentation given by Mike Anderson, Pharm.D, Chief Pharmacy Officer, UnitedHealthcare Medicare & Retirement at Market Access USA, he highlights the demographic, regulatory and marketplace changes to Medicare Part D and how they will impact you. Download this presentation and learn: Overview of UnitedHealth Group Demographic Changes Regulatory Changes Marketplace Changes Download the presentation now To learn more …

How long will markets sustain high priced orphan drugs?

The orphan drug market was worth more than $50 billion in 2011 and turns out blockbusters at the same rate as the broader industry, according to a recent Thomson Reuters analysis. This is mostly due to the high-prices of therapies developed by the industry for rare disease patients. Even though the segment has just started to provide a great source …